↓ Skip to main content

Carnosine retards tumor growth in vivo in an NIH3T3-HER2/neu mouse model

Overview of attention for article published in Molecular Cancer, January 2010
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (75th percentile)
  • Good Attention Score compared to outputs of the same age and source (67th percentile)

Mentioned by

twitter
2 X users
wikipedia
1 Wikipedia page

Citations

dimensions_citation
71 Dimensions

Readers on

mendeley
48 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Carnosine retards tumor growth in vivo in an NIH3T3-HER2/neu mouse model
Published in
Molecular Cancer, January 2010
DOI 10.1186/1476-4598-9-2
Pubmed ID
Authors

Christof Renner, Nadine Zemitzsch, Beate Fuchs, Kathrin D Geiger, Matthias Hermes, Jan Hengstler, Rolf Gebhardt, Jürgen Meixensberger, Frank Gaunitz

Abstract

It was previously demonstrated that the dipeptide carnosine inhibits growth of cultured cells isolated from patients with malignant glioma. In the present work we investigated whether carnosine also affects tumor growth in vivo and may therefore be considered for human cancer therapy.

Timeline

Login to access the full chart related to this output.

If you don’t have an account, click here to discover Explorer

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 48 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Iran, Islamic Republic of 1 2%
United Kingdom 1 2%
Unknown 46 96%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 15 31%
Student > Master 11 23%
Researcher 5 10%
Student > Bachelor 3 6%
Student > Doctoral Student 2 4%
Other 8 17%
Unknown 4 8%
Readers by discipline Count As %
Agricultural and Biological Sciences 14 29%
Medicine and Dentistry 6 13%
Chemistry 5 10%
Biochemistry, Genetics and Molecular Biology 5 10%
Pharmacology, Toxicology and Pharmaceutical Science 2 4%
Other 9 19%
Unknown 7 15%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 February 2017.
All research outputs
#6,109,191
of 22,664,644 outputs
Outputs from Molecular Cancer
#411
of 1,713 outputs
Outputs of similar age
#39,874
of 163,824 outputs
Outputs of similar age from Molecular Cancer
#12
of 37 outputs
Altmetric has tracked 22,664,644 research outputs across all sources so far. This one has received more attention than most of these and is in the 72nd percentile.
So far Altmetric has tracked 1,713 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.7. This one has done well, scoring higher than 75% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 163,824 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 75% of its contemporaries.
We're also able to compare this research output to 37 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 67% of its contemporaries.